Rocket receives $150m credit facility to advance cardiovascular portfolio
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing…
All articles by Salong Debbarma
Salong Debbarma
-
-
Gilead Sciences signs five-year DevOps agreement with Cognizant
Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of…
-
Pacira partners with Molteni for Exparel commercialisation
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across…
-
AstraZeneca opens new R&D centre in Cambridge, US
AstraZeneca has opened a new global strategic research and development (R&D) facility in Massachusetts, US, as part of an investment…
-
FDA approves expanded indication for Lilly’s Jaypirca
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib) as…
-
Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US
Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US. The facility will be…
-
Bristol Myers Squibb secures expanded US approval for Camzyos
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to…
-
BioMarin and Profluent partner on AI-designed enzyme therapies
BioMarin Pharmaceutical has entered a research collaboration with Profluent to design and optimise novel enzyme therapies for its drug development…
-
OBIO marks $704m funding milestone for Canadian health tech ventures
Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively…
-
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab)…